US FDA places clinical hold on Intellia's two gene-editing treatment trials

Core Insights - Intellia Therapeutics announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its two late-stage trials for an experimental gene-editing therapy targeting a rare disease [1] Company Summary - The clinical hold affects two late-stage trials that were testing the gene-editing therapy [1] - The company is focused on developing innovative treatments using gene-editing technology [1] Industry Summary - The gene-editing therapy sector is facing regulatory scrutiny, as evidenced by the FDA's decision to impose a clinical hold [1] - This incident highlights the challenges and risks associated with advancing experimental therapies in the biotechnology industry [1]